CGT-4859
- Generic Name
- CGT-4859
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, AdultFGFR2 Gene Fusion/RearrangementFGFR2 Gene AmplificationFGFR2 Gene Short VariantsFGFR3 Gene Fusion/RearrangementFGFR3 Gene AmplificationFGFR3 Gene Short VariantsFGFR2 Genetic Alterations
- Interventions
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06777316
- Locations
- 🇺🇸
Fox Chase cancer Center, Philadelphia, Pennsylvania, United States
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath